Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma
Table 2
p values for MGMT comparison in tumour core (column 2) and margin (column 3) and for comparing core against margin in methylated (column 4) and in unmethylated (column 5).
Immunooncology targets and controls
Tumour core
Tumour margin
Methylated
Unmethylated
Methylated versus unmethylated
Methylated versus unmethylated
Core versus margin
Core versus margin
CD4
0.005
0.452
0.050
0.452
CD14
0.006
0.246
0.117
0.246
CD68
0.007
0.416
0.316
0.416
CD8A
0.011
0.383
0.617
0.383
B7-H3
0.023
0.793
0.087
0.793
PD-L1
0.025
0.639
0.875
0.639
CD19
0.028
0.614
0.406
0.614
FOXP3
0.030
0.722
0.577
0.722
CD44
0.032
0.451
0.068
0.451
STAT3 (phospho Y705)
0.034
0.396
0.048
0.396
CD45
0.041
0.358
0.125
0.358
Pan Cytokeratin
0.048
0.370
0.617
0.370
MS4A1/CD20
0.053
0.347
0.738
0.347
CD45RO
0.093
0.438
0.379
0.438
S6
0.100
0.218
0.928
0.218
PD1
0.121
0.390
0.205
0.390
CD3
0.144
0.830
0.259
0.830
Beta-2 microglobulin
0.147
0.423
0.981
0.423
VISTA
0.153
0.663
0.624
0.663
Bcl2
0.230
0.376
0.499
0.376
GZMB
0.274
0.317
0.155
0.317
PTEN
0.292
0.239
0.790
0.239
Beta-catenin
0.296
0.025
0.473
0.025
CD56
0.357
0.860
0.105
0.860
Ki-67
0.378
0.279
0.358
0.279
STAT3
0.634
0.619
0.841
0.619
AKT
0.946
0.644
0.207
0.644
P-Akt
0.978
0.353
0.505
0.353
Bold Values statistically significant after Benjamini–Hochberg adjustment for False Discovery Rate at 0.1. Values statistically significant if unadjusted but not statistically significant after Benjamini–Hochberg adjustment for False Discovery Rate at 0.1.
